CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
提高实体瘤中 CAR-T 细胞持久性的策略
英文原题：Strategies for Improving CAR T Cell Persistence in Solid Tumors.
查看英文原题
Strategies for Improving CAR T Cell Persistence in Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞需要优化才能在实体瘤患者中有效。有许多障碍影响其成功的能力。其中一个障碍是持久性，因为要实现最佳的抗肿瘤反应，输注的 CAR-T 细胞必须植入并持续存在。这一单一变量受到多种因素的影响——CAR-T 细胞设计、使用的淋巴细胞清除方案、生成 T 细胞产品的扩增方法等。此外，可以利用外部制剂来增强 CAR-T 细胞，例如在体外扩增过程中或 CAR-T 细胞输注后添加新型细胞因子、促进记忆形成的药物或其他制剂，以支持它们在恶劣的肿瘤微环境中生存。本综述重点介绍了许多用于优化 T 细胞持久性的策略，以及改善输注细胞持久性的未来方向。
展开英文摘要原文
CAR T cells require optimization to be effective in patients with solid tumors. There are many barriers affecting their ability to succeed. One barrier is persistence, as to achieve an optimal antitumor response, infused CAR T cells must engraft and persist. This singular variable is impacted by a multitude of factors-the CAR T cell design, lymphodepletion regimen used, expansion method to generate the T cell product, and more.
Additionally, external agents can be utilized to augment CAR T cells, such as the addition of novel cytokines, pharmaceutical drugs that bolster memory formation, or other agents during either the ex vivo expansion process or after CAR T cell infusion to support them in the oppressive tumor microenvironment. This review highlights many strategies being used to optimize T cell persistence as well as future directions for improving the persistence of infused cells.
论文信息
- 作者
- Wittling MC、Cole AC、Brammer B、Diatikar KG、Schmitt NC、Paulos CM
- 单位
- Department of Surgery/Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.United States
- 文献类型
- 综述
- 期刊
- Cancers2024 Aug 16
- 原文标识
- PubMed 39199630 · DOI 10.3390/cancers16162858
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →